Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies

prnewswire.com/news-releases/novo-nordisk-announces-that-cvs-caremark-the-countrys-largest-pbm-has-decided-wegovy-will-be-the-preferred-glp-1-medicine-covered-for-obesity-on-its-template-formularies-302443603.html

Wegovy® will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1, 2025
- Novo Nordisk is focused on new ways to drive access and affordability for Wegovy®, the…

This story appeared on prnewswire.com, 2025-05-01 14:36:22.643000.